It is a structural analogue of human glucagon-like peptide 1 (GLP-1), which can mimic its effect, reduce hunger, reduce diet, and reduce calorie intake
I think I think the overall conclusion from this [paper] is that there is some evidence that pharmacotherapy for obesity changes food preferences in some people, he said
Getting started The GLP-1 telehealth market exists, but profit depends on solid systems from day one
This initial dose is not intended to produce weight loss
For individuals with multiple risk factors, clinicians should engage in shared decision-making , weighing the substantial metabolic benefits of GLP-1 therapy against potential gallbladder complications
If you are still exploring whether GLP-1 medication is the right fit, take the free assessment quiz to get started